Advertisement
Product › Details
lurbinectedin (PM1183)
Next higher product group | cancer drug_o | |
Status | 2017-05-17 development p3 existent | |
Organisation | PharmaMar S.A. (MSE: PHM) | |
Group | PharmaMar (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for lurbinectedin (PM1183)
- [1] PharmaMar S.A.. (2/17/20). "Press Release: PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer". Madrid & Dublin....
- [2] PharmaMar S.A.. (3/25/19). "Press Release: PharmaMar Announces Positive Results in Its Lurbinectedin Monotherapy Trial for Small Cell Lung Cancer". Madrid....
- [3] PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid)....
- [4] PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top